- 0QCV, 4AB, ABBV Ticker
- F, XETRA, LSE, NYSE Exchange
- 30,000 Employees
- 💊 Health Care Sector
- 🧪 Biotechnology Industry
- Richard A. Gonzalez CEO
245 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
Financial statements — AbbVie
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
46B | 33B | 33B | 28B | 26B |
| Cost Of Revenue |
|
15B | 7.4B | 7.7B | 7B | 5.8B |
| Gross Profit |
|
30B | 26B | 25B | 21B | 20B |
| Research and Development |
|
6.6B | 6.4B | 10B | 5B | 4.4B |
| Selling General and Admin |
|
11B | 6.9B | 7.4B | 6.3B | 5.9B |
| Operating Expense |
|
33B | 21B | 25B | 18B | 16B |
| Operating Income |
|
13B | 12B | 7.3B | 9.9B | 9.6B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
13B | 12B | 7.3B | 9.9B | 9.6B |
| Interest Income |
|
2.3B | 1.5B | 1.1B | 1B | 970M |
| Pretax Income |
|
3.4B | 8.4B | 5.2B | 7.7B | 7.9B |
| Income Tax |
|
-1.2B | 540M | -490M | 2.4B | 1.9B |
| Minority Interest |
|
6M | 0 | 0 | 0 | 0 |
| Net Income |
|
4.6B | 7.8B | 5.7B | 5.3B | 5.9B |
| Net Income Basic |
|
4.6B | 7.8B | 5.7B | 5.3B | 5.9B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
8.5B | 40B | 8.1B | 9.8B | 6.4B |
| Short term investments |
|
3.6B | 2.4B | 1.9B | 4.7B | 3.6B |
| Receivables |
|
8.8B | 5.4B | 5.4B | 5.1B | 4.8B |
| Inventory |
|
3.3B | 1.8B | 1.6B | 1.6B | 1.4B |
| Other current assets |
|
3.6B | 2.4B | 1.9B | 4.7B | 3.6B |
| Current assets |
|
24B | 50B | 17B | 21B | 16B |
| Long term investments |
|
130B | 40B | 42B | 50B | 50B |
| Property plant equipment |
|
5.2B | 3B | 2.9B | 2.8B | 2.6B |
| Goodwill |
|
33B | 16B | 16B | 16B | 15B |
| Intangible assets |
|
83B | 19B | 21B | 28B | 29B |
| Other assets |
|
4.9B | 2.3B | 1.2B | 1.3B | 1.2B |
| Total assets |
|
150B | 89B | 59B | 71B | 66B |
| Accounts payable |
|
2.3B | 1.5B | 1.5B | 1.5B | 1.4B |
| Current long term debt |
|
8.5B | 3.8B | 5.3B | 6.4B | 400M |
| Other current liabilities |
|
18B | 10B | 10B | 8.8B | 8B |
| Total current liabilities |
|
29B | 16B | 17B | 17B | 9.8B |
| Long term debt |
|
78B | 63B | 35B | 31B | 36B |
| Other liabilities |
|
28B | 18B | 14B | 16B | 8.4B |
| Minority Interest |
|
21M | 0 | 0 | 0 | 0 |
| Total Liabilities |
|
140B | 97B | 68B | 66B | 61B |
| Common stock |
|
1.7B | 1.5B | 1.5B | 1.6B | 1.6B |
| Retained earning |
|
1.1B | 4.7B | 3.4B | 5.5B | 4.4B |
| Treasury stock |
|
-2.3B | -25B | -24B | -12B | -11B |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
13B | -8.2B | -8.4B | 5.1B | 4.6B |
| Net tangible assets |
|
-100B | -42B | -45B | -38B | -40B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
4.6B | 7.8B | 5.7B | 5.3B | 5.9B |
| Depreciation |
|
6.5B | 2B | 1.8B | 1.5B | 1.2B |
| Changes in receivables |
|
3.4B | 44M | 300M | 330M | 28M |
| Changes in inventories |
|
1.5B | 210M | 0 | 160M | -280M |
| Cash change |
|
-31B | 32B | -1.7B | 3.4B | -2B |
| Cash flow |
|
18B | 13B | 13B | 10B | 7B |
| Capital expenditures |
|
-800M | -550M | -640M | -530M | -480M |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-38B | 600M | -1B | -270M | -6.1B |
| Dividends paid |
|
• | • | • | • | • |
| Net borrowings |
|
74B | 24B | 30B | 23B | 27B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
-12B | 19B | -14B | -5.5B | -3.9B |
| Exchange rate effect |
|
• | • | • | • | • |
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.